Immuno Oncology Summit
Immuno Oncology Summit
  • Register Today
  • Final Agenda Now Available
  • Sponsorship Opportunities
  • Posters

Meet Thought Leaders in Cancer Immunotherapy at the Premier Annual IO Event
As our understanding of tumor immunology has advanced, immuno-oncology has made unprecedented progress in improving the outcomes for cancer patients. Still, with the field in its infancy, the full curative potential of IO has yet to be realized. CHI’s 4th Annual Immuno-Oncology Summit has been designed to support a coordinated effort by industry players to bring commercial immunotherapies and immunotherapy combinations through clinical development and into the market. This weeklong, nine-meeting set will include topics ranging from early discovery through clinical development as well as emerging areas such as oncolytic virotherapy. Overall, this event will provide a focused look at how researchers are applying new science and technology in the development of the next generation of effective and safe immunotherapies.

Who Will Attend?
Scientific leaders, C-level executives, professors, site directors and researchers from pharma, biotech, academia, and government working in the areas of immuno-oncology, immunotherapy, antibody and protein engineering, biomarker discovery, immunology, cell and gene therapy, and preclinical and clinical development

Conference Tracks

 

Immunomodulatory Therapeutic Antibodies for CancerOncolytic Virus ImmunotherapyTS: Immunotherapy for Drug DiscoveryRational Combination Cancer ImmunotherapyPersonalized ImmunotherapyPreclinical and Translational Immuno-OncologyAdoptive T Cell TherapyBiomarkers for Immuno-OncologyClinical Trials for Cancer Immunotherapy  
Immunomodulatory Therapeutic Antibodies for CancerOncolytic Virus ImmunotherapyTS: Immunotherapy for Drug DiscoveryRational Combination Cancer ImmunotherapyPersonalized ImmunotherapyPreclinical and Translational Immuno-OncologyAdoptive T Cell TherapyBiomarkers for Immuno-OncologyClinical Trials for Cancer Immunotherapy  

Plenary Keynote Presentations:

Matthew GoldsteinA New Era of Personalized Therapy: Using Tumor Neoantigens to Unlock the Immune System

Matthew J. Goldstein, M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc.

Neon Therapeutics, Inc. launched in 2015 to focus on advancing neoantigen biology to improve cancer patient care. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. The company’s first trial will launch later this year investigating the combination of a personalized, vaccine with nivolumab in advanced Melanoma, NSCLC, and Bladder Cancer.

Michael RosenzweigEmerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses

Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories

Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.

Morganna FreemanReading Tea Leaves: The Dilemma of Prediction and Prognosis in Immunotherapy

Morganna Freeman, D.O., Medical Oncologist, Immunotherapeutics, The Angeles Clinic and Research Institute

With the rapid expansion of immunotherapeutics in oncology, scientifically significant advances have been made with both the depth and duration of antitumor responses. However, not all patients benefit, or quickly relapse, thus much scientific inquiry has been devoted to appropriate patient selection and how such obstacles might be overcome. While more is known about potential biomarkers, accurate prognostication persists as a knowledge gap, and efforts to bridge it will be discussed here.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Download Brochure
2016 The Immuno-Oncology Summit Brochure

Corporate Sponsors

Abzena

Personal Genome Diagnostics

Pieris Pharmaceuticals

Systems Imagination


View All Sponsors

View Media Partners

Sponsor & Exhibitor Information

Exhibitor Prospectus

Download 2016 Sponsor and Exhibitor Prospectus